View Post

Novel Adjuvant Strategies Reshape HER2+ Breast Cancer Treatment

In In The News by Barbara Jacoby

By: Jax DiEugenio From: onclive.com Following the publication of the KATHERINE trial (NCT01772472), a number of novel clinical trials have emerged with the use of antibody-drug conjugates (ADCs), checkpoint inhibitors, and TKIs aimed at further improving outcomes for patients with high-risk, early-stage HER2-positive breast cancer, according to Paolo Tarantino, MD. In the second part of an interview with OncLive®, Tarantino …

View Post

Researchers link 9 blood proteins to breast cancer and suggest 3 drugs for repurposing

In In The News by Barbara Jacoby

By: Hugo Francisco de Souza From: news-medical.net In a recent study in the journal Communication Biology, researchers employed a novel combined Mendelian randomization (MR) analysis to identify 62 plasma proteins (including 9 with robust support, 13 with medium support, and 40 with limited support) associated with breast cancer and its Luminal A or B subtypes. Unlike previous approaches using only …

View Post

MRI-based nomogram predicts breast cancer treatment response

In In The News by Barbara Jacoby

By: Amerigo Allegretto From: auntminnie.com Pretreatment breast MRI can help quantify intratumoral heterogeneity (ITH) and predict pathologic complete response in women undergoing breast cancer treatment, according to research published April 15 in Radiology. A team led by Yao Huang, PhD, from Chongqing University in China developed a nomogram that combined ITH scoring and clinicopathologic variables. It highlighted the nomogram’s high-achieving …

View Post

Cancer pill gave me ‘four years of extra time’

In In The News by Barbara Jacoby

By: Philippa Roxby From: bbc.com Linda Kelly, 67, has advanced breast cancer which has spread to her bones and chest wall, but says a new pill has given her extra years of life and time to travel with her husband. “It does let you have a normal kind of life and you forget you have cancer,” she says of the …

View Post

Novel compounds target dual enzymes to combat hormone-resistant breast cancer

In In The News by Barbara Jacoby

By: University of Birmingham From: medicalxpress.com Researchers have found new compounds that could be used to treat a common breast cancer that can be resistant to hormone therapies. Published in the journal RSC Medicinal Chemistry, new research targets two critical enzymes involved in the production of the hormone estrogen —aromatase and steroid sulfatase—at the same time. Estrogen receptor-positive (ER+) breast …

View Post

What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases

In In The News by Barbara Jacoby

By: Jeff Hall From: diagnosticimaging.com Emerging research from the recent Society of Interventional Radiology (SIR) conference suggests the combination of transarterial radioembolization (TARE) and immunotherapy may offer improved three-year survival outcomes for patients with breast cancer and liver metastases. For patients with breast cancer liver metastases, the combination of immunotherapy and transarterial radioembolization (TARE) may significantly enhance survival outcomes over …

View Post

Researchers Identify Key Signaling Pathway Disruptions Driving Breast Cancer Treatment Resistance

In In The News by Barbara Jacoby

By: Alexandra Gerlach, Associate Editor From: pharmacytimes.com Key Takeaways Disruptions in PI3K/Akt/mTOR signaling pathways drive oncogenesis and treatment resistance in breast cancer, affecting 25%-40% of cases. Dysregulation of cellular signaling pathways, including PI3K/Akt/mTOR and RAS/RAF/MEK/ERK, promotes tumor growth and therapy resistance. Emerging treatments focus on targeted therapies, immunotherapies, and novel drug delivery systems to improve precision targeting and overcome resistance. …

View Post

Nanotechnology innovation aims to improve breast cancer treatment

In In The News by Barbara Jacoby

Source: The University of Queensland From: news-medical.net University of Queensland researchers are designing nanotechnology they believe could improve how we treat the most aggressive form of breast cancer. Professor Chengzhong (Michael) Yu and his team are developing novel nanoparticles that could dramatically increase the effectiveness of immunotherapies when treating triple-negative breast cancer (TNBC). TNBC is aggressive, fast-growing and accounts for …

View Post

Immunotherapies Spark Excitement in Triple-Negative Breast Cancer Treatment

In In The News by Barbara Jacoby

By: Tony Berberabe, MPH From: targetedonc.com THE USE OF IMMUNOTHERAPY approaches in triple-negative breast cancer (TNBC) has resulted in diverse breakthroughs that leverage immune checkpoint inhibitors (ICIs). Expanded use of ICIs has led to the identification of different molecular subtypes that can help develop individualized treatment plans. Investigators in numerous trials are exploring immunotherapy in combination with existing treatment modalities …

View Post

What Are the Side Effects of Breast Cancer Treatment?

In In The News by Barbara Jacoby

From: healthline.com Side effects of breast cancer treatment often go away once treatment is over, but some can be long term. Side effect management might include home remedies and prescription medications. Breast cancer treatment options vary widely from person to person. Most people undergo some kind of surgery, but many also receive other treatments, such as chemotherapy, radiation, hormone therapy, …